Severe COVID: A challenge for rheumatologists
Main Article Content
Keywords
coronavirus, Rheumatic diseases, fisher test
Abstract
The pandemic was a dark time, during which severe COVID and rheumatologic diseases revealed a gap in management. The lack of in-depth analysis on the effects of immunosuppressants on the immune response to SARS-CoV-2 leaves unanswered questions. With small sample sizes and uncertain results, it is urgent to revisit previous databases with the aim of conducting more robust, long-term studies to elucidate how thrombocytopenia and immunosuppressive management influence fatal outcomes in rheumatic patients. Are we ignoring the obvious?
References
1. Galicia-Lucas UJ, Ramírez-Pérez AA. COVID-19 grave y desenlace en pacientes con enfermedades reumáticas. Rev Med Inst Mex Seguro Soc. 2021;59(2):127-132.
2. Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19. Ann Rheum Dis.2020;79(6):S737-9. doi: 10.1136/annrheumdis-2020-217460.
3. Hyrich KL, Machado PM. Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol. 2021 Feb;17(2):71-72. doi: 10.1038/s41584-020-00562-2.
4. Páramo JA. Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes. Reumatol Clin (Engl Ed). 2022;18(1):1–4. doi:10.1016/j.reuma.2020.06.008.
5. Cajamarca-Baron J, Guavita-Navarro D, Buitrago-Bohorquez J, Gallego-Cardona L, Navas A, Cubides H, et al. SARS-CoV-2 (COVID-19) en pacientes con algún grado de inmunosupresión. Reumatol Clin. 2021;17(7):408–419. doi:10.1016/j.reuma.2020.08.005.
6. Gracia-Ramos, A. E., & Saavedra-Salinas, M. Á. (2021). Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Rheumatology International, 41(4), 799–809.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.